SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist...
- Mechanism
- Curator reviewed
SPC2968 is a potent inhibitor of hypoxia inducible transcription factor (HIF-1±), which serves as the key sensor of cellular hypoxia in response to which it transcriptionally up-regulates a host of genes that play important roles in promotion of cancers, including angiogenesis, apoptosis, cell migration and metastasis. HIF-1± protein is essentially undetectable in normal cells, but reaches high intracellular concentrations in a variety of cancers where it is strongly correlated with poor prognosis and resistance to therapy. SPC2968 thus has the potential to become a broad, multiple mode-of-action and highly cancer cell selective drug. [Santaris Pharmaceuticals Website]
- Primary indication
- Investigated for use/treatment in solid tumors and lymphoma (unspecified).Curator reviewed
- Code names
- ENZ2968 · RO7070179 · SPC2968
What you can answer from here — as of August 08, 2024
Which companies are running trials of SPC2968, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account